Joseph J. Cullen, MD, FACS

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Joseph J. Cullen, MD, FACS sits in the upper quartile of US sponsors by registered trial count (#3,663 of 15,742 sponsors by registered trial count).

3 total trials none currently recruiting 2 completed early-phase tilt upper quartile by trial count

Joseph J. Cullen, MD, FACS: 3 sponsored US clinical trials, none currently recruiting.

Joseph J. Cullen, MD, FACS sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small-Cell Lung Carcinoma, with 1 trials.

Upper-quartile sponsor footprint

Joseph J. Cullen, MD, FACS sits in the upper quartile of the sponsor corpus (#3,663 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

How the Joseph J. Cullen, MD, FACS early-phase archive is shaped

3 indexed studies, none listed as recruiting (0% open); 2 completed (67%).

Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Non-Small-Cell Lung Carcinoma (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Joseph J. Cullen, MD, FACS: archived-pipeline peers nationwide

Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Joseph J. Cullen, MD, FACS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-07-11 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Joseph J. Cullen, MD, FACS10xBio22nd Century GroupAA SecordAAADRS Clinical Research Center23andMe3-C Institute for Social Development3 Waves Wellness3EO Health
Joseph J. Cullen, MD, FACS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-07-11 snapshot).

Joseph J. Cullen, MD, FACS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Joseph J. Cullen, MD, FACS page

3 registered trials is a research-attention snapshot, not an endorsement of Joseph J. Cullen, MD, FACS or any single study.

  • None of Joseph J. Cullen, MD, FACS's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Non-Small-Cell Lung Carcinoma is the condition Joseph J. Cullen, MD, FACS studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small-Cell Lung Carcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Joseph J. Cullen, MD, FACS pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.